| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Perilla ketone targets the lungs, where it is activated by pulmonary P450 cytochrome enzymes. This activation leads to the production of reactive metabolites that cause severe lung injury and diffuse pulmonary edema. The compound's anti-inflammatory, antioxidant, and anticancer properties suggest that it may interact with various cellular targets including inflammatory mediators, redox systems, and signaling pathways involved in cancer progression.
|
|---|---|
| ln Vitro |
In vitro, Perilla ketone has been found to exhibit various biological activities including anti-inflammatory, antioxidant, and anticancer properties. The compound modulates inflammatory responses, reduces oxidative stress, and inhibits cancer cell proliferation. However, specific in vitro activity data for Perilla ketone are limited. Its toxicity in the lungs is mediated through metabolic activation by cytochrome P450 enzymes.
|
| ln Vivo |
In vivo, Perilla ketone is known for its pulmonary toxicity. The compound can be activated by pulmonary P450 cytochrome enzymes in the lungs, leading to severe lung injury and the development of diffuse pulmonary edema. This toxicity is a significant concern for exposure to the compound. Despite its toxicity, Perilla ketone has also been studied for its potential anti-inflammatory, antioxidant, and anticancer properties.
|
| Enzyme Assay |
Non-cell-based assays for Perilla ketone involve characterization of its chemical properties. The compound's structure is confirmed by NMR and MS. Its purity is determined by GC. Metabolic activation studies using liver microsomes or recombinant P450 enzymes can be performed to study the compound's metabolism and the formation of reactive intermediates. The compound's chemical properties are characterized.
|
| Cell Assay |
Cellular assays for Perilla ketone are performed using various cell lines including lung epithelial cells, immune cells, and cancer cells. Cells are treated with the compound at various concentrations, and cellular responses are measured. Cell viability is measured by MTT assays. Anti-inflammatory activity is evaluated by measuring pro-inflammatory cytokine production. Antioxidant activity is assessed by measuring ROS levels. The compound's cytotoxicity in lung cells is of particular interest due to its pulmonary toxicity.
|
| Animal Protocol |
In vivo experiments with Perilla ketone are conducted in animal models to study its pulmonary toxicity. Animals are administered the compound via oral or inhalation routes, and lung injury is assessed by measuring inflammatory markers, pulmonary edema, and histological analysis of lung tissues. The compound's anti-inflammatory, antioxidant, and anticancer properties may also be evaluated in appropriate models.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Perilla ketone have not been extensively characterized. As a monoterpene with a molecular weight of 166.22, the compound is expected to have moderate oral bioavailability and good tissue penetration. Its absorption, distribution, metabolism, and excretion are not well-defined. The compound is metabolized by pulmonary P450 enzymes. Comprehensive PK studies are needed.
|
| Toxicity/Toxicokinetics |
The toxicity of Perilla ketone is well-documented. The compound can be activated by pulmonary P450 cytochrome enzymes in the lungs, leading to severe lung injury and the development of diffuse pulmonary edema. This toxicity is a significant concern and limits the therapeutic potential of the compound. Comprehensive toxicological studies have been conducted due to the compound's pulmonary toxicity.
|
| References | |
| Additional Infomation |
Perillaldehyde is an aromatic ketone. It has been reported that perillaldehyde exists in perilla, wrinkled perilla, and other organisms with relevant data.
Perilla ketone (CAS# 553-84-4) is a natural monoterpene compound with the molecular formula C₁₀H₁₄O₂ and a molecular weight of 166.22. It is also known as 1-(3-Furanyl)-4-methyl-1-pentanone. Perilla ketone is found in the essential oils of Perilla frutescens and exhibits anti-inflammatory, antioxidant, and anticancer properties. However, it can be activated by pulmonary P450 enzymes leading to severe lung injury and pulmonary edema. As of current knowledge, Perilla ketone is not approved as a therapeutic agent. |
| Molecular Formula |
C10H14O2
|
|---|---|
| Molecular Weight |
166.22
|
| Exact Mass |
166.099
|
| CAS # |
553-84-4
|
| PubChem CID |
68381
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
0.976g/cm3
|
| Boiling Point |
224.4ºC at 760mmHg
|
| Flash Point |
96.8ºC
|
| Index of Refraction |
1.465
|
| LogP |
2.898
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
12
|
| Complexity |
152
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(C)CCC(=O)C1=COC=C1
|
| InChi Key |
LVHLZMUFIYAEQB-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H14O2/c1-8(2)3-4-10(11)9-5-6-12-7-9/h5-8H,3-4H2,1-2H3
|
| Chemical Name |
1-(furan-3-yl)-4-methylpentan-1-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (601.61 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.0161 mL | 30.0806 mL | 60.1612 mL | |
| 5 mM | 1.2032 mL | 6.0161 mL | 12.0322 mL | |
| 10 mM | 0.6016 mL | 3.0081 mL | 6.0161 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
